Tustumi Francisco
Department of Gastroenterology, Universidade de São Paulo, São Paulo, Brazil.
Department of Surgery, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Front Med (Lausanne). 2022 Jun 24;9:941464. doi: 10.3389/fmed.2022.941464. eCollection 2022.
Achalasia is a primary esophageal dysmotility disorder. Despite the high volume of studies addressing the conventional treatments for achalasia, few are debated regarding the non-conventional treatments, such as cardiectomy, cardioplasty, endoluminal substances injection (ethanolamine oleate, polidocanol, botulinum toxin), stents, and certain drugs (beta-agonists, anticholinergic, nitrates, calcium channel blockers, and phosphodiesterase inhibitors).
A critical review was performed.
Endoscopic, surgical, and pharmacological treatments were included. A qualitative synthesis was presented.
Non-conventional therapeutic options for treating achalasia encompass medical, endoscopic, and surgical procedures. Clinicians and patients need to know all the tools for the management of achalasia. However, several currently available studies of non-conventional treatments lack high-quality evidence, and future randomized trials are still needed.
贲门失弛缓症是一种原发性食管动力障碍性疾病。尽管针对贲门失弛缓症的传统治疗方法已有大量研究，但对于诸如贲门切除术、贲门成形术、腔内物质注射（油酸乙醇胺、聚多卡醇、肉毒杆菌毒素）、支架置入以及某些药物（β-激动剂、抗胆碱能药物、硝酸盐、钙通道阻滞剂和磷酸二酯酶抑制剂）等非传统治疗方法的讨论却很少。
进行了一项批判性综述。
纳入了内镜、手术和药物治疗。进行了定性综合分析。
治疗贲门失弛缓症的非传统治疗选择包括医学、内镜和外科手术。临床医生和患者需要了解贲门失弛缓症管理的所有方法。然而，目前关于非传统治疗的多项现有研究缺乏高质量证据，仍需要未来的随机试验。
